Traumatic brain injury (TBI) significantly decreases cyclic AMP (cAMP) signaling which produces long-term synaptic plasticity deficits and chronic learning and memory impairments. Phosphodiesterase 4 (PDE4) is a major family of cAMP hydrolyzing enzymes in the brain and of the four PDE4 subtypes, PDE4D in particular has been found to be involved in memory formation. Although most PDE4 inhibitors target all PDE4 subtypes, PDE4D can be targeted with a selective, negative allosteric modulator, D159687. In this study, we hypothesized that treating animals with D159687 could reverse the cognitive deficits caused by TBI. To test this hypothesis, adult male Sprague Dawley rats received sham surgery or moderate parasagittal fluid-percussion brain injury. After 3 months of recovery, animals were treated with D159687 (0.3 mg/kg, intraperitoneally) at 30 min prior to cue and contextual fear conditioning, acquisition in the water maze or during a spatial working memory task. Treatment with D159687 had no significant effect on these behavioral tasks in non-injured, sham animals, but did reverse the learning and memory deficits in chronic TBI animals. Assessment of hippocampal slices at 3 months post-TBI revealed that D159687 reversed both the depression in basal synaptic transmission in area CA1 as well as the late-phase of long-term potentiation. These results demonstrate that a negative allosteric modulator of PDE4D may be a potential therapeutic to improve chronic cognitive dysfunction following TBI.
A negative allosteric modulator of PDE4D enhances learning after traumatic brain injury A B S T R A C T Traumatic brain injury (TBI) significantly decreases cyclic AMP (cAMP) signaling which produces long-term synaptic plasticity deficits and chronic learning and memory impairments. Phosphodiesterase 4 (PDE4) is a major family of cAMP hydrolyzing enzymes in the brain and of the four PDE4 subtypes, PDE4D in particular has been found to be involved in memory formation. Although most PDE4 inhibitors target all PDE4 subtypes, PDE4D can be targeted with a selective, negative allosteric modulator, D159687. In this study, we hypothesized that treating animals with D159687 could reverse the cognitive deficits caused by TBI. To test this hypothesis, adult male Sprague Dawley rats received sham surgery or moderate parasagittal fluid-percussion brain injury. After 3 months of recovery, animals were treated with D159687 (0.3 mg/kg, intraperitoneally) at 30 min prior to cue and contextual fear conditioning, acquisition in the water maze or during a spatial working memory task. Treatment with D159687 had no significant effect on these behavioral tasks in non-injured, sham animals, but did reverse the learning and memory deficits in chronic TBI animals. Assessment of hippocampal slices at 3 months post-TBI revealed that D159687 reversed both the depression in basal synaptic transmission in area CA1 as well as the late-phase of long-term potentiation. These results demonstrate that a negative allosteric modulator of PDE4D may be a potential therapeutic to improve chronic cognitive dysfunction following TBI.
Introduction
Traumatic brain injury (TBI) is a significant public health problem affecting 1.74 million people per year in the United States (Faul, Xu, Wald, & Coronado, 2010) . Over 40% of TBI patients discharged after hospitalization develop long-term disabilities resulting from the brain trauma (Faul et al., 2010) . The number of people living with chronic disabilities resulting from TBI is estimated to range from 3.2 to 5.3 million in the United States (Selassie et al., 2008; Zaloshnja, Miller, Langlois, & Selassie, 2008) . A common symptom of TBI is cognitive difficulty, with learning and memory impairments reported in nearly 80% of chronic TBI survivors (Frieden, Houry, & Baldwin, 2015) . Therapeutics to improve cognition in the chronic recovery phase of TBI have had some success. Cognitive rehabilitation has the strongest empirical support to improve recovery after TBI, but pharmacotherapies targeting particular molecular pathways have yet to achieve clinical trial success (Cicerone et al., 2011) .
Preclinical research studies of TBI have found that deficits in activating cAMP response-element binding protein (CREB) may underlie hippocampal learning deficits in the chronic recovery phase of TBI (Titus, Furones, Kang, & Atkins, 2013) . Basal levels of phospho-CREB are reduced at 3 months after TBI and treatment with rolipram, a panphosphodiesterase 4 (PDE4) inhibitor rescues deficits in activation of phospho-CREB after fear conditioning in TBI animals (Titus, Furones et al., 2013; Titus et al., 2016) . Inhibition of all PDE4 enzymes in the brain or PDE4B selectively to increase CREB phosphorylation improves TBI-induced cognitive dysfunction (Titus, Furones, et al., 2013; Titus et al., 2016) . Several PDE4 subtypes are elevated in the hippocampus after TBI, suggesting that particular PDE4 subtypes may be viable therapeutic targets (Wilson, Titus, Oliva, Furones, & Atkins, 2016) . There currently are two PDE4 inhibitors approved by the FDA, roflumilast and apremilast. These are competitive inhibitors of all PDE4
